Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05242458 · ClinicalTrials.gov registry record
A Study of Ustekinumab Treatment in Children With Crohn's Disease
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 545
- Enrollment target
NCT05242458: Completed study, sponsored by Janssen Research & Development.
NCT05242458 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 545 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05242458 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 545 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of ustekinumab in achieving clinical remission in pediatric participants (greater than or equal to \[\>=\] 2 to less than \[\<\] 18 years and weight \>= 40 kilograms \[kg\] at baseline).
Primary Outcome
Percentage of Pediatric participants with clinical remission at Week 52 will be reported. Clinical remission is defined by short pediatric Crohn's disease activity index (sPCDAI) less than or equal to (\<=) 10.
Interventions
- DRUG Ustekinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2023-05-22 |
What the finished NCT05242458 record still lists
NCT05242458 is an observational study that tracks outcomes without assigning an intervention. The registered 545 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ustekinumab is the first listed.
NCT05242458 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05242458 about?
NCT05242458 is a clinical study titled "A Study of Ustekinumab Treatment in Children With Crohn's Disease". The purpose of this study is to evaluate the effectiveness of ustekinumab in achieving clinical remission in pediatric participants (greater than or equal to \[\>=\] 2 to less than \[\<\] 18 years and weight \>= 40 kilograms \[kg\] at baseline).
What is the current status of trial NCT05242458?
This trial is currently completed. The enrollment target is 545 participants. The study started on 2022-03-21. Estimated completion is 2023-05-22.
What interventions are being tested in trial NCT05242458?
The interventions under investigation include: Ustekinumab (DRUG).
Who is sponsoring clinical trial NCT05242458?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04553523 · 545 participants · NA
Hydrus® Microstent New Enrollment Post-Approval Study
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI